Home / Health / MS Hope: Cancer Therapy Trials Show Promise
MS Hope: Cancer Therapy Trials Show Promise
15 Mar
Summary
- CAR-T therapy, a cancer treatment, is being tested for multiple sclerosis.
- The experimental treatment targets rogue B cells implicated in MS.
- Early trials show potential, but caution and further research are needed.
A novel cancer therapy, CAR-T, is undergoing early-stage clinical trials as a potential treatment for multiple sclerosis (MS). This experimental approach reprograms a patient's immune cells to identify and attack the overactive B cells that damage the central nervous system in MS.
Grace Miller, diagnosed with MS at 24, is participating in a trial at Cleveland Clinic. After years of debilitating symptoms and ineffective treatments, she enrolled in the CAR-T therapy trial in 2023. The treatment involves a one-time infusion of modified T cells designed to target the B cells responsible for MS.
Researchers hope CAR-T therapy can eliminate B cells in both the bloodstream and the brain, where current MS treatments struggle to reach. Dr. Jeffrey Cohen of Cleveland Clinic highlighted that this approach leverages existing experience from cancer therapy, offering a potential advantage.
However, the trials are in their initial phases, and success is not guaranteed. Experts like Dr. Rhonda Voskuhl caution that existing antibody therapies are already effective, and it remains uncertain if CAR-T will offer significant improvements, especially for progressive MS.
Risks associated with CAR-T therapy include cytokine release syndrome and neurotoxicity. Researchers are carefully monitoring these potential complications, particularly in MS patients. Regardless of the outcome, these trials are expected to yield valuable insights into the immune system's role in MS.
